Crossmark

Inactivation of Capicua drives cancer metastasis

Crossref DOI link: https://doi.org/10.1038/ng.3728

Published Online: 2016-11-21

Published Print: 2017-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Okimoto, Ross A

Breitenbuecher, Frank

Olivas, Victor R

Wu, Wei

Gini, Beatrice

Hofree, Matan

Asthana, Saurabh

Hrustanovic, Gorjan

Flanagan, Jennifer

Tulpule, Asmin

Blakely, Collin M

Haringsma, Henry J

Simmons, Andrew D

Gowen, Kyle

Suh, James

Miller, Vincent A

Ali, Siraj

Schuler, Martin

Bivona, Trever G
License Information

Text and Data Mining valid from 2016-11-21
More Information

Article History

Received: 28 July 2016

Accepted: 25 October 2016

First Online: 21 November 2016

Competing interests

: H.J.H. and A.D.S. are employees of Clovis Oncology. K.G., J.S., V.A.M., and S. Ali are employees of Foundation Medicine. T.G.B. is a consultant to Novartis, Astellas, Array Biopharma, Ariad, Teva, and Astrazeneca, and has received research funding from Ignyta.